Aquestive Therapeutics (AQST) announced that two poster presentations highlighting results from the investigational use of Anaphylm Sublingual Film in the treatment of severe allergic reactions, including anaphylaxis, will be presented at the Center for Food Allergy and Asthma Research, CFAAR, Food Allergy Summit , which will be held June 27-29 in Chicago, Ill. The data from these posters was originally presented at the 2025 AAAAI Annual Meeting. If approved by the U.S. Food and Drug Administration, FDA, Anaphylm would be the first and only orally delivered epinephrine option for the treatment of severe allergic reactions in the United States.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Positive Outlook for Aquestive Therapeutics Amidst FDA Progress and Strategic Preparations for Anaphylm Launch
- Buy Rating for Aquestive Therapeutics Driven by Anaphylm’s FDA Progress and Market Potential
- FDA Accepts Aquestive’s New Drug Application for Anaphylm
- Aquestive announces FDA acceptance of NDA, PDUFA date for Anaphylm
- Aquestive Therapeutics Holds Annual Stockholders Meeting